OncoMatch/Clinical Trials/NCT06788938
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Is NCT06788938 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tarlatamab treatment for dll3-expressing tumors.
Treatment: Tarlatamab treatment — This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: DLL3 overexpression (≥25% (Stage 1) or ≥1% (Stage 2) by IHC)
Positive DLL3 expression by immunohistochemistry on tumor biopsy. Positive DLL3 expression, for purposes of this study, defined as at least 25% for participants enrolling into Stage 1 or 1% for participants enrolling into Stage 2.
Disease stage
Required: Stage IV, III
Metastatic disease required
Must be stage IV (metastatic); participants with stage III disease are eligible provided that they are not candidates for surgery and/or radiotherapy with curative intent. Measurable disease, as per RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy — if a standard of care therapy exists for the tumor type
Participants must have progressed on or following at least one line of therapy, if a standard of care therapy exists for the tumor type.
Cannot have received: selective inhibitor of the DLL3 pathway
Prior therapy with any selective inhibitor of the DLL3 pathway.
Lab requirements
Blood counts
ANC ≥ 1.0 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
eGFR (MDRD) ≥ 30 mL/min/1.73 m2
Liver function
Serum total bilirubin ≤ 1.5 x ULN (except Gilbert's disease); AST (SGOT) and ALT (SGPT) ≤ 3 x ULN (≤ 5 x ULN for patients with liver metastasis or primary liver cancer)
Adequate organ function as defined in Table 3 below. Hematological: ANC ≥ 1.0 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 9 g/dL. Renal: eGFR (MDRD) ≥ 30 mL/min/1.73 m2. Hepatic: Serum total bilirubin ≤ 1.5 x ULN (except Gilbert's disease); AST (SGOT) and ALT (SGPT) ≤ 3 x ULN (≤ 5 x ULN for patients with liver metastasis or primary liver cancer).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Davis Comprehensive Cancer Center · Davis, California
- UCI Health Chao Family Comprehensive Cancer Center · Irvine, California
- University of California at Los Angeles · Los Angeles, California
- UC San Diego Moores Cancer Center · San Diego, California
- University of California at San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify